Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Enfusion stock (Enfusion)

Buy Enfusion stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Enfusion, which produces Cloud-based investment management software, wrapped its IPO, selling 15.322 million shares at $17 per share, the high end of its announced price range.

Shares of Enfusion will begin trading on the NYSE later today under the ticker symbol ENFN, but shares are available for limit orders on Robinhood and other platforms.

Our top picks for where to buy Enfusion stock

Top pick for advanced traders

Go to site
Get up to $5,000 cash
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Our pick for transfer bonus

Go to site
Get up to $10,000 cash
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • No-cost financial planning and automated investing

Our pick for Investing by theme

Go to site
Earn up to $300 on new deposits
  • Trade $0 commission stocks & ETFs with as little as $1
  • Theme and ETF screener
  • Discover new opportunities with Opto's AI-driven classification system

How to buy Enfusion stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – ENFN. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Enfusion stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 5 of 5
Name Product Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Finder Score: 4.4 / 5: ★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
Stocks, Options, Mutual funds, ETFs, Alternatives
Get up to $10,000 cash
Commission-free stocks, ETFs and options, with no options per-contract fees. Plus, a no-cost robo-advisor and complimentary access to certified financial planners (CFPs).
Finder Score: 3.1 / 5: ★★★★★
Stocks, ETFs
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
Finder Score: 4.3 / 5: ★★★★★
Stocks, Options, ETFs
Up to 8.10%
Get up to 15 free stocks
No commission stock, ETF and options trades, with $0 equity options contract fees, low margin rates and advanced trading tools.
Finder Score: 4.2 / 5: ★★★★★
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
Get up to $10,000 and transfer fees covered
Build a diversified portfolio of stocks, bonds, options, ETFs, crypto and alternative assets, with a high-yield cash account and options contract rebates.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Enfusion stock price (NYSE: ENFN)

Use our graph to track the performance of ENFN stocks over time.

Enfusion shares at a glance

Information last updated 2024-07-21.
Latest market close$9.25
52-week range$7.52 - $11.01
50-day moving average $8.87
200-day moving average $9.09
Wall St. target price$9.96
PE ratio 462.5
Dividend yield N/A (0%)
Earnings per share (TTM) $0.02

Is it a good time to buy Enfusion stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Enfusion price performance over time

Historical closes compared with the close of $9.25 from 2024-07-19

1 week (2024-07-16) 0.54%
1 month (2024-06-21) 11.18%
3 months (2024-04-23) -1.07%
6 months (2024-01-23) 3.12%
1 year (2023-07-21) -14.83%
2 years (2022-07-22) -18.43%
3 years (2021-07-19) N/A
5 years (2019-07-19) N/A

Is Enfusion stock undervalued or overvalued?

Valuing Enfusion stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Enfusion's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Enfusion's P/E ratio

Enfusion's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 463x. In other words, Enfusion shares trade at around 463x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

However, Enfusion's P/E ratio is best considered in relation to those of others within the software - application industry or those of similar companies.

Enfusion's EBITDA

Enfusion's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $13.1 million.

The EBITDA is a measure of a Enfusion's overall financial performance and is widely used to measure a its profitability.

To put Enfusion's EBITDA into context you can compare it against that of similar companies.

Enfusion financials

Revenue TTM $181.6 million
Gross profit TTM $103.2 million
Return on assets TTM 3.31%
Return on equity TTM 4.18%
Profit margin 1.4%
Book value $0.65
Market Capitalization $850.2 million

TTM: trailing 12 months

Enfusion share dividends

We're not expecting Enfusion to pay a dividend over the next 12 months.

You may also wish to consider:

Enfusion share price volatility

Over the last 12 months, Enfusion's shares have ranged in value from as little as $7.52 up to $11.01. A popular way to gauge a stock's volatility is its "beta".

ENFN.US volatility(beta: 0.92)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Enfusion's is 0.923. This would suggest that Enfusion's shares are less volatile than average (for this exchange).

To put Enfusion's beta into context you can compare it against those of similar companies.

Enfusion overview

Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. It also offers Accounting/General Ledger System, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion Analytics System, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion, Inc. was founded in 1997 and is headquartered in Chicago, Illinois. .

Frequently asked questions

What percentage of Enfusion is owned by insiders or institutions?
Currently 7.607% of Enfusion shares are held by insiders and 96.015% by institutions.
How many people work for Enfusion?
Latest data suggests 1,102 work at Enfusion.
When does the fiscal year end for Enfusion?
Enfusion's fiscal year ends in December.
Where is Enfusion based?
Enfusion's address is: 125 South Clark Street, Chicago, IL, United States, 60603
What is Enfusion's ISIN number?
Enfusion's international securities identification number is: US2928121043

More guides on Finder

Ask a question provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site